Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment.

Abstract

The polymorphism of 14-bp tandem repeat sequence located in the ASNS gene probably acts as a transcriptional enhancer element and leads to higher expression of the gene in carriers of more than 2 repeats (>R2). We searched for an association with disease outcome in 264 children with ALL. A multivariate proportional hazard regression model adjusted for age at diagnosis (HR (95%CI)=1.05 (1.04-1.09)) and high-risk group (HR(95%CI)=3.47 (1.74-6.88)) revealed that R3 carriers with a poor response at day 15 had an increased risk of events, HR (95%CI)=2.72 (1.06-6.96). These results suggest a conditional interaction between the ASNS polymorphism and an early response to chemotherapy among pediatric patients with ALL.

• Authors: Agata Pastorczak, Wojciech Fendler, Beata Zalewska-Szewczyk, Patryk Górniak, Monika Lejman, Joanna Trelińska, Justyna Walenciak, Jerzy Kowalczyk, Tomasz Szczepanski, Wojciech Mlynarski, Polish Pediatric Leukemia/Lymphoma Study Group
• Journal: Leukemia research (Leuk Res) Vol. 38 Issue 2 Pg. 180-3 (Feb 2014) ISSN: 1873-5835 [Electronic] England
• PMID: 24268318 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Aspartate-Ammonia Ligase

Topics

• Adolescent
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Aspartate-Ammonia Ligase (genetics)
• Child
• Child, Preschool
• Drug Resistance, Neoplasm (genetics)
• Female
• Genotype
• Humans
• Infant
• Male
• Polymorphism, Genetic
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, epidemiology, genetics)
• Treatment Outcome